Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 2 mg/ml (equivalent: noradrenaline (norepinephrine), qty 1 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions). as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 2 mg/ml (equivalent: noradrenaline (norepinephrine), qty 1 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions). as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; maize starch - 1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes. b) due to dual av nodal pathways in patients with debilitating symptoms. c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms.,although flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide sandoz tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; maize starch; microcrystalline cellulose; croscarmellose sodium; magnesium stearate - 1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes. b) due to dual av nodal pathways in patients with debilitating symptoms. c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms.,although flecainide may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecainide sandoz tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - primaquine phosphate, quantity: 13.2 mg (equivalent: primaquine, qty 7.5 mg) - tablet, uncoated - excipient ingredients: wheat starch; povidone; purified water; lactose monohydrate; purified talc; gelatin; magnesium stearate; glycerol - prevention of relapses (radical cure) of malaria caused by p.vivax and p. ovale. adjunctive therapy in the treatment of gametocytemia due to p.falciparum in patients resident in areas receptive to malaria.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: maize starch; colloidal anhydrous silica; pregelatinised maize starch; magnesium stearate; titanium dioxide; gelatin; sodium lauryl sulfate; sorbitan monolaurate - ursosan is indicated in the treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - phenylephrine hydrochloride, quantity: 0.1 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - phenylephrine hydrochloride is intended for the maintenance of an adequate level of blood pressure during spinal and inhalation anaesthesia. it is also employed to overcome paroxysmal supraventricular tachycardia.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - bupivacaine hydrochloride monohydrate, quantity: 5.28 mg/ml (equivalent: bupivacaine hydrochloride, qty 5 mg/ml) - injection, solution - excipient ingredients: glucose; water for injections; sodium hydroxide - bupivacaine spinal heavy bnm is indicated for the production of spinal anaesthesia.,bupivacaine spinal heavy bnm is suitable for abdominal surgery lasting 45 - 60 minutes and urological and lower limb surgery lasting 2 - 3 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 20 mg (equivalent: noradrenaline (norepinephrine), qty 10 mg) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sumpathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).,as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate, quantity: 12 mg (equivalent: noradrenaline (norepinephrine), qty 6 mg) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sumpathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).,as an adjunct in the treatment of cardiac arrest. to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.